Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 2/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.39 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.39 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.39 |
| ▸ | TUBB | P07437 | 1/20 | 0.39 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.39 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.39 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.39 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.39 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.39 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.39 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.39 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.39 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.39 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.39 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.39 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.39 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7195818 | 0.81 | CA1 (0.32) | — | |
| SCHEMBL6745346 | 0.79 | TAAR1 (0.47) | ABCB1TAAR1SIGMAR1HRH3 | |
| SCHEMBL28065890 | 0.77 | CALM1 (0.50) | ABCB1PTGER4PTGER2KMT2AMEN1 | |
| SCHEMBL15863787 | 0.73 | ABL1 (0.45) | ABCB1 | |
| SCHEMBL6913106 | 0.72 | LIPG (0.35) | — | |
| SCHEMBL27506183 | 0.72 | TAAR1 (0.40) | TAAR1 | |
| SCHEMBL7189551 | 0.70 | CA1 (0.32) | — | |
| SCHEMBL6912877 | 0.70 | LIPG (0.44) | — | |
| SCHEMBL8962391 | 0.70 | LIPG (0.44) | — | |
| SCHEMBL834551 | 0.70 | TAAR1 (0.73) | TAAR1SIGMAR1TUBB4ATUBBTUBA3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063951-A1 | Alkaloid halide salts of swainsonine and methods of use | GLYCODESIGN HOLDINGS LTD. (CA) | 2004-04-01 | — | — | US | disclosed |
| US-20030105326-A1 | Alkaloid halide salts of swainsonine and methods of use | DENNIS JAMES W (CA) | 2003-06-05 | — | — | US | disclosed |
| EP-1264832-A1 | Alkaloid halide salts of swainsonine and methods of use | Glycodesign Inc. (CA) | 2002-12-11 | — | — | EP | disclosed |
| EP-0975632-B1 | ALKALOID HALIDE SALTS OF SWAINSONINE AND METHODS OF USE | GLYCODESIGN INC (CA) | 2002-10-16 | — | — | EP | disclosed |
| US-6395745-B1 | STABLE, CRYSTAL STRUCTURE; PLANT EXTRACT | GLYCODESIGN, INC. (CA) | 2002-05-28 | — | — | US | disclosed |
| EP-0975632-A1 | ALKALOID HALIDE SALTS OF SWAINSONINE AND METHODS OF USE | Glycodesign Inc. (CA) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998046602-A1 | ALKALOID HALIDE SALTS OF SWAINSONINE AND METHODS OF USE | GLYCODESIGN INC. (CA) | 1998-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105326-A1 | Alkaloid halide salts of swainsonine and methods of use | SLC6A12, PWWP2B, WNK2 | ABCB1 1997/4885TAAR1 1112/4885SIGMAR1 994/4885 |
| US-20040063951-A1 | Alkaloid halide salts of swainsonine and methods of use | SLC6A12, TUBB3, HNMT | ABCB1 3059/4885TAAR1 733/4885SIGMAR1 851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.